Cargando…

Diagnostic Challenges of CD4(+)/CD56(+)/CD123(+) hematological neoplasms

Detalles Bibliográficos
Autores principales:	Thiago, Leandro S., Sandes, Alex Freire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Dermatologia 2013
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3760959/ https://www.ncbi.nlm.nih.gov/pubmed/24068155 http://dx.doi.org/10.1590/abd1806-4841.20132799

Ejemplares similares

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
por: Cai, Tianyu, et al.
Publicado: (2022)

CD4+CD56+ Lineage Negative Hematopoietic Neoplasm : So Called Blastic NK Cell Lymphoma
por: Kim, Yoonjung, et al.
Publicado: (2005)

CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
por: Testa, Ugo, et al.
Publicado: (2019)

Human BDCA2(+)CD123(+)CD56(+) dendritic cells (DCs) related to blastic plasmacytoid dendritic cell neoplasm represent a unique myeloid DC subset
por: Yu, Haisheng, et al.
Publicado: (2015)

CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms
por: Chen, Xin, et al.
Publicado: (2020)

What is CD4+CD56+ malignancy and how should it be treated?
por: Reimer, P, et al.
Publicado: (2003)

Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms
por: Arlindo, Elissandra Machado, et al.
Publicado: (2017)

The diagnostic power of CD117, CD13, CD56, CD64, and MPO in rapid screening acute promyelocytic leukemia
por: Tran, Vinh Thanh, et al.
Publicado: (2020)

Alterations in the CD56(−) and CD56(+) T Cell Subsets during COVID-19
por: Vavilova, Julia D., et al.
Publicado: (2023)

Local CD4+, CD8+ and CD56+ T-lymphocite Reaction on Primary Lung Cancer
por: Jusufovic, Edin, et al.
Publicado: (2011)

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
por: Testa, Ugo, et al.
Publicado: (2014)

Scientific comment on: “Quantitative flow cytometric evaluation of CD200, CD123, CD43 and CD52 as a tool for the differential diagnosis of mature B-cell neoplasms”()
por: Ikoma, Maura Rosane Valerio
Publicado: (2017)

CD3, CD4, CD8, CD19 and CD16/CD56 positive cells in tuberculosis infection and disease: Peculiar features in children
por: Venturini, Elisabetta, et al.
Publicado: (2019)

Coclustering CD45 with CD4 or CD8 alters the phosphorylation and kinase activity of p56lck
Publicado: (1990)

CD3+, CD56+, CD4−, CD8−, CD20−, CD30− Peripheral T-Cell Non-Hodgkin's Lymphoma: A Rare Case Report
por: Jagati, Ashish, et al.
Publicado: (2017)

CD4+CD56+CD68+hematopoietic tumor of probable plasmacytoid monocyte derivation with weak expression of cytoplasmic CD3.
por: Ko, Young Hyeh, et al.
Publicado: (2002)

Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar
por: Mutka, Minna, et al.
Publicado: (2023)

Quantitative serum determination of CD3, CD4, CD8, CD16, and CD56 in women with primary infertility: The role of cell-mediated immunity
por: Shakerian, Behzad, et al.
Publicado: (2022)

Analysis of CD4, CD8, CD19, CD56-16, CD64, QuantiFERON biomarkers in exudative lymphocyte-dominant pleural effusion
por: Mehraban, Zahra, et al.
Publicado: (2022)

CD56(dim)CD16(high) and CD56(bright)CD16(−) cell percentages associated with maximum knee extensor strength and incidence of death in elderly
por: Senpuku, Hidenobu, et al.
Publicado: (2016)

Acute Myeloid Leukemia With MLL Rearrangement and CD4+/CD56+ Expression can be Misdiagnosed as Blastic Plasmacytoid Dendritic Cell Neoplasm: Two Case Reports
por: Lee, Ju-Mee, et al.
Publicado: (2016)

56 Increased Frequency of CD4+ CD25+ FOXP3- in Allergic Conjunctivitis Patients
por: Galicia-Carreón, Jorge, et al.
Publicado: (2012)

CD56(bright) natural killer cells preferentially kill proliferating CD4(+) T cells
por: Lee, Mercede, et al.
Publicado: (2023)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

The phenotype of CD3–CD56(bright) and CD3–CD56(dim) natural killer cells in systemic lupus erythematosus patients and its relation to disease activity
por: Soelistyoningsih, Dwi, et al.
Publicado: (2022)

Runx3d controls the abundance and functional differentiation of CD4(+)CD8αα(+) intraepithelial T cells
por: Li, Can, et al.
Publicado: (2023)

CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm
por: Bôle-Richard, Elodie, et al.
Publicado: (2022)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
por: Pelosi, Elvira, et al.
Publicado: (2023)

The DC-SIGN-CD56 interaction inhibits the anti-dendritic cell cytotoxicity of CD56 expressing cells
por: Nabatov, Alexey A., et al.
Publicado: (2015)

Distinct Signatures in the Receptor Repertoire Discriminate CD56bright and CD56dim Natural Killer Cells
por: Schwane, Vera, et al.
Publicado: (2020)

Development Of [(211)At]Astatine-Based Anti-CD123 Radioimmunotherapy For Acute Leukemias and Other CD123+ Malignancies
por: Laszlo, George S., et al.
Publicado: (2022)

The frequencies of peripheral blood CD5(+)CD19(+) B cells, CD3(−)CD16(+)CD56(+) NK, and CD3(+)CD56(+) NKT cells and serum interleukin-10 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder
por: Khani, Leila, et al.
Publicado: (2022)

Correlation of CD19(+)CD24(hi)CD38(hi) B cells in coronary artery disease with severity of atherosclerosis
por: Liu, Yang, et al.
Publicado: (2020)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Identification of Cytolytic CD161(−)CD56(+) Regulatory CD8 T Cells in Human Peripheral Blood
por: Hu, Dan, et al.
Publicado: (2013)

Multiples aberrant phenotypes in multiple myeloma patient expressing CD56(-), CD28(+),CD19(+)
por: Leite, Luiz Arthur Calheiros, et al.
Publicado: (2012)

Activation of Blood CD3(+)CD56(+)CD8(+) T Cells during Pregnancy and Multiple Sclerosis
por: de Andrés, Clara, et al.
Publicado: (2017)

Survival outcomes of CD34(+)CD38(−)LSCs and their expression of CD123 in adult AML patients
por: Zahran, Asmaa M., et al.
Publicado: (2018)

How the Discovery of the CD4/CD8-p56(lck) Complexes Changed Immunology and Immunotherapy
por: Rudd, Christopher E.
Publicado: (2021)

Evaluation of CD56(dim) and CD56(bright) natural killer cells in peripheral blood of women with IVF failures
por: Mardanian, Farahnaz, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mjun8np5ccjib6l562qmi922jc